skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 210  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Patlak Slope versus Standardized Uptake Value Image Quality in an Oncologic PET/CT Population: A Prospective Cross-Sectional Study
Material Type:
Article
Add to My Research

Patlak Slope versus Standardized Uptake Value Image Quality in an Oncologic PET/CT Population: A Prospective Cross-Sectional Study

Diagnostics (Basel), 2024-05, Vol.14 (9), p.883 [Peer Reviewed Journal]

COPYRIGHT 2024 MDPI AG ;2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2075-4418 ;EISSN: 2075-4418 ;DOI: 10.3390/diagnostics14090883 ;PMID: 38732298

Full text available

2
Editorial: Bridging the gap to molecular imaging and theranostics
Material Type:
Article
Add to My Research

Editorial: Bridging the gap to molecular imaging and theranostics

Frontiers in nuclear medicine, 2024-04, Vol.4 [Peer Reviewed Journal]

EISSN: 2673-8880 ;DOI: 10.3389/fnume.2024.1385097

Full text available

3
Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum
Material Type:
Book
Add to My Research

Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum

ISBN: 9783031335327 ;ISBN: 3031335333 ;ISBN: 9783031335334 ;ISBN: 3031335325 ;DOI: 10.1007/978-3-031-33533-4

Digital Resources/Online E-Resources

4
A Drug-Target Interaction Prediction Based on Supervised Probabilistic Classification
Material Type:
Article
Add to My Research

A Drug-Target Interaction Prediction Based on Supervised Probabilistic Classification

Journal of computer science, 2023-10, Vol.19 (10), p.1203-1211

ISSN: 1549-3636 ;EISSN: 1552-6607 ;DOI: 10.3844/jcssp.2023.1203.1211

Full text available

5
Case report: Peptide receptor radioligand therapy in metastatic pediatric neuroendocrine tumors
Material Type:
Article
Add to My Research

Case report: Peptide receptor radioligand therapy in metastatic pediatric neuroendocrine tumors

Frontiers in nuclear medicine, 2023-08, Vol.3 [Peer Reviewed Journal]

ISSN: 2673-8880 ;EISSN: 2673-8880 ;DOI: 10.3389/fnume.2023.1193880

Full text available

6
Optimization of Radiolabeling of a [ 90 Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell Transplantation
Material Type:
Article
Add to My Research

Optimization of Radiolabeling of a [ 90 Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell Transplantation

Cancers, 2023-07, Vol.15 (14), p.3660 [Peer Reviewed Journal]

2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2023 by the authors. 2023 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers15143660 ;PMID: 37509321

Full text available

7
India's Growing Nuclear Medicine Infrastructure and Emergence of Radiotheranostics in Cancer Care: Associated Challenges and the Opportunities to Collaborate
Material Type:
Article
Add to My Research

India's Growing Nuclear Medicine Infrastructure and Emergence of Radiotheranostics in Cancer Care: Associated Challenges and the Opportunities to Collaborate

Indian journal of nuclear medicine, 2023-07, Vol.38 (3), p.201-207 [Peer Reviewed Journal]

Copyright: © 2023 Indian Journal of Nuclear Medicine 2023 ;ISSN: 0972-3919 ;EISSN: 0974-0244 ;DOI: 10.4103/ijnm.ijnm_77_23

Full text available

8
Optimization of Radiolabeling of a [[sup.90]Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell Transplantation
Material Type:
Article
Add to My Research

Optimization of Radiolabeling of a [[sup.90]Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell Transplantation

Cancers, 2023-07, Vol.15 (14) [Peer Reviewed Journal]

COPYRIGHT 2023 MDPI AG ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers15143660

Full text available

9
India's growing nuclear medicine infrastructure and emergence of radiotheranotics in cancer care: Associated challenges and the opportunities to collaborate
Material Type:
Article
Add to My Research

India's growing nuclear medicine infrastructure and emergence of radiotheranotics in cancer care: Associated challenges and the opportunities to collaborate

Indian journal of nuclear medicine, 2023-07, Vol.38 (3), p.201-207 [Peer Reviewed Journal]

COPYRIGHT 2023 Medknow Publications and Media Pvt. Ltd. ;2023. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 0972-3919 ;EISSN: 0974-0244 ;DOI: 10.4103/ijnm.ijnm_77_23

Full text available

10
Personalized [177Lu]Lutetium-PSMA Therapy for Patients with Pre-Treated Castration-Resistant Prostate Cancer: A Single Institution Experience from a Comprehensive Cancer Centre
Material Type:
Article
Add to My Research

Personalized [177Lu]Lutetium-PSMA Therapy for Patients with Pre-Treated Castration-Resistant Prostate Cancer: A Single Institution Experience from a Comprehensive Cancer Centre

Cancers, 2023-06, Vol.15 (12), p.3216 [Peer Reviewed Journal]

COPYRIGHT 2023 MDPI AG ;2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2023 by the authors. 2023 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers15123216 ;PMID: 37370826

Full text available

11
Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study
Material Type:
Article
Add to My Research

Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study

The Journal of nuclear medicine (1978), 2023-04, Vol.64 (4), p.574-578 [Peer Reviewed Journal]

Copyright Society of Nuclear Medicine Apr 1, 2023 ;2023 by the Society of Nuclear Medicine and Molecular Imaging. 2023 ;ISSN: 0161-5505 ;EISSN: 1535-5667 ;DOI: 10.2967/jnumed.122.264456 ;PMID: 36302656

Full text available

12
Safety and Survival Outcomes of 177 Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223 Ra treatment: The RALU Study
Material Type:
Article
Add to My Research

Safety and Survival Outcomes of 177 Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223 Ra treatment: The RALU Study

Journal of Nuclear Medicine, 2023-04, Vol.64 (4), p.574-578 [Peer Reviewed Journal]

2023 by the Society of Nuclear Medicine and Molecular Imaging. ;ISSN: 0161-5505 ;EISSN: 1535-5667 ;EISSN: 2159-662X ;DOI: 10.2967/jnumed.122.264456 ;PMID: 36302656

Full text available

13
Predictive and prognostic potential of pretreatment 68 Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer (mCRPC)
Material Type:
Article
Add to My Research

Predictive and prognostic potential of pretreatment 68 Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.200-200 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2023.41.6_suppl.200

Full text available

14
Time interval between radium-223 ( 223 Ra) therapy and Lutetium-177–prostate-specific membrane antigen ( 177 Lu-PSMA) treatment and outcomes in the RALU study
Material Type:
Article
Add to My Research

Time interval between radium-223 ( 223 Ra) therapy and Lutetium-177–prostate-specific membrane antigen ( 177 Lu-PSMA) treatment and outcomes in the RALU study

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.73-73 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2023.41.6_suppl.73

Full text available

15
Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA
Material Type:
Article
Add to My Research

Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA

Frontiers in oncology, 2022-12, Vol.12, p.1066926-1066926 [Peer Reviewed Journal]

Copyright © 2022 Assadi, Manafi-Farid, Jafari, Keshavarz, Divband, Moradi, Adinehpour, Samimi, Dadgar, Jokar, Mayer and Prasad 2022 Assadi, Manafi-Farid, Jafari, Keshavarz, Divband, Moradi, Adinehpour, Samimi, Dadgar, Jokar, Mayer and Prasad ;ISSN: 2234-943X ;EISSN: 2234-943X ;DOI: 10.3389/fonc.2022.1066926

Full text available

16
Poster Presentation
Material Type:
Article
Add to My Research

Poster Presentation

Indian journal of nephrology, 2022-12, Vol.32 (7), p.19-166 [Peer Reviewed Journal]

COPYRIGHT 2022 Medknow Publications and Media Pvt. Ltd. ;2022. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 0971-4065 ;EISSN: 1998-3662 ;DOI: 10.4103/0971-4065.362512

Full text available

17
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
Material Type:
Article
Add to My Research

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225

EJNMMI research, 2022-10, Vol.12 (1), p.65-11, Article 65 [Peer Reviewed Journal]

The Author(s) 2022 ;2022. The Author(s). ;The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2191-219X ;EISSN: 2191-219X ;DOI: 10.1186/s13550-022-00935-6 ;PMID: 36182983

Full text available

18
Editorial: Response assessment of radioligand therapies
Material Type:
Article
Add to My Research

Editorial: Response assessment of radioligand therapies

Frontiers in oncology, 2022-07, Vol.12, p.904337-904337 [Peer Reviewed Journal]

Copyright © 2022 Lopci and Prasad 2022 Lopci and Prasad ;ISSN: 2234-943X ;EISSN: 2234-943X ;DOI: 10.3389/fonc.2022.904337 ;PMID: 35965585

Full text available

19
Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma
Material Type:
Article
Add to My Research

Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma

Pharmaceutics, 2022-07, Vol.14 (7), p.1466 [Peer Reviewed Journal]

2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 by the authors. 2022 ;ISSN: 1999-4923 ;EISSN: 1999-4923 ;DOI: 10.3390/pharmaceutics14071466 ;PMID: 35890361

Full text available

20
European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease
Material Type:
Article
Add to My Research

European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease

Journal of neuroendocrinology, 2022-07, Vol.34 (7) [Peer Reviewed Journal]

Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0953-8194 ;ISSN: 1365-2826 ;EISSN: 1365-2826 ;DOI: 10.1111/jne.13146 ;PMID: 35613326

Digital Resources/Online E-Resources

Results 1 - 20 of 210  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (158)

Refine My Results

Creation Date 

From To
  1. Before 2007  (9)
  2. 2007 To 2010  (19)
  3. 2011 To 2014  (39)
  4. 2015 To 2019  (68)
  5. After 2019  (76)
  6. More options open sub menu

Language 

  1. English  (207)
  2. Japanese  (3)
  3. German  (2)
  4. Spanish  (2)
  5. Portuguese  (1)
  6. More options open sub menu

Searching Remote Databases, Please Wait